Olodaterol: all 57 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to InhaleCompletedNCT04223843Phase 4Results posted
• The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the DiskusCompletedNCT03240575Phase 4Results posted
• Cardiovascular Function in COPD PatientsCompletedNCT03055988Phase 4Results posted
• Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD PatientsCompletedNCT02969317Phase 1Results posted
• Effect of Tiotropium + Olodaterol on Breathlessness in COPD PatientsCompletedNCT02853123Phase 4Results posted
• Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD PatientsCompletedNCT02629965Phase 3Results posted
• Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.CompletedNCT02296138Phase 3Results posted
• Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02231177Phase 1Results posted
• To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of AirwaysCompletedNCT02085161Phase 3Results posted
• Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different InhalersCompletedNCT02030535Phase 2Results posted
• Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)CompletedNCT02006732Phase 3Results posted
• Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD PatientsCompletedNCT01969721Phase 3Results posted
• Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)CompletedNCT01964352Phase 3Results posted
• A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.CompletedNCT01703845Phase 1Results posted
• Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®CompletedNCT01696058Phase 3Results posted
• Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®CompletedNCT01694771Phase 3Results posted
• Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary DiseaseCompletedNCT01559116Phase 3Results posted
• Japan Long-term Safety for Tiotropium Plus OlodaterolCompletedNCT01536262Phase 3Results posted
• Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.CompletedNCT01533935Phase 3Results posted
• Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD PatientsCompletedNCT01533922Phase 3Results posted
• A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPDCompletedNCT01525615Phase 3Results posted
• Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01431287Phase 3Results posted
• Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01431274Phase 3Results posted
• Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry IICompletedNCT01040793Phase 3Results posted
• A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01040728Phase 3Results posted
• Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01040689Phase 3Results posted
• Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01040403Phase 2Results posted
• Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry ICompletedNCT01040130Phase 3Results posted
• A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.CompletedNCT01013753Phase 2Results posted
• Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00932646Phase 3Results posted
• Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00931385Phase 3Results posted
• Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent AsthmaCompletedNCT00928668Phase 2Results posted
• BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPDCompletedNCT00846768Phase 2Results posted
• Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPDCompletedNCT00824382Phase 2Results posted
• Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease IICompletedNCT00796653Phase 3Results posted
• Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease ICompletedNCT00793624Phase 3Results posted
• 12 / 48 wk Pivotal PFT vs PBO in COPD IICompletedNCT00782509Phase 3Results posted
• 12 / 48 Week Pivotal PFT vs PBO in COPD ICompletedNCT00782210Phase 3Results posted
• Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00720499Phase 2Results posted
• Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)CompletedNCT00696020Phase 2Results posted
• Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With AsthmaCompletedNCT00467740Phase 2Results posted
• Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.CompletedNCT00452400Phase 2Results posted
• Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPDCompletedNCT05927155Phase 3
• Effects of Tiotropium/Olodaterol on Cardio-pulmonary Exercise Capacity in Patients With Hyperinflated Chronic Obstructive Pulmonary Disease [ACHIEVE]CompletedNCT04994574Not applicable
• Effects of Dual Bronchodilator Treatment on Cardiopulmonary Interactions in COPDCompletedNCT03425617Phase 4
• INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and OlodaterolCompletedNCT03152149Phase 4
• Ultra-long Acting Bronchodilator Therapy in Smoking AsthmaticsCompletedNCT02682862Phase 4
• Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male VolunteersCompletedNCT02259946Phase 1
• Investigation of the Metabolism and Pharmacokinetics of [14C]BI 1744 CL and [14C]BI 1744 CL Administered as an Oral Solution in Healthy Male SubjectsCompletedNCT02172157Phase 1
• Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female VolunteersCompletedNCT02172144Phase 1
• Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male SubjectsTerminatedNCT02172131Phase 1
• Multiple Rising Inhalative Doses of BI 1744 CL in Healthy Male VolunteersCompletedNCT02172105Phase 1
• Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionCompletedNCT02171832Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BI 1744 CL in Healthy Male and Female VolunteersCompletedNCT02171806Phase 1
• Single Rising Peroral Doses of BI 1744 CL in Healthy VolunteersCompletedNCT02171793Phase 1
• A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female VolunteersCompletedNCT02171780Phase 1
• Olodaterol Bridging Study in AsthmaWithdrawnNCT01428622Phase 2

← Olodaterol overview